Loading…
Romidepsin-associated cardiac toxicity and ECG changes: A case report and review of the literature
Background Romidepsin is a novel histone deacetylase inhibitor that is approved for the treatment of cutaneous and peripheral T-cell lymphoma in patients who have had at least one prior therapy. Romidepsin is generally well tolerated, though it comes with a risk of cardiac toxicities. Objective We r...
Saved in:
| Published in: | Journal of oncology pharmacy practice 2018-01, Vol.24 (1), p.56-62 |
|---|---|
| Main Authors: | , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c431t-5e5d37b197e9530f7b58d0ef80d423808eba5595f00b1eaeaa8c9512dd56d8973 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c431t-5e5d37b197e9530f7b58d0ef80d423808eba5595f00b1eaeaa8c9512dd56d8973 |
| container_end_page | 62 |
| container_issue | 1 |
| container_start_page | 56 |
| container_title | Journal of oncology pharmacy practice |
| container_volume | 24 |
| creator | Rivers, Zachary T Oostra, Drew R Westholder, James S Vercellotti, Gregory M |
| description | Background
Romidepsin is a novel histone deacetylase inhibitor that is approved for the treatment of cutaneous and peripheral T-cell lymphoma in patients who have had at least one prior therapy. Romidepsin is generally well tolerated, though it comes with a risk of cardiac toxicities.
Objective
We report a case of electrocardiogram changes in a 64-year-old male with enteropathy-associated T-cell lymphoma, type 2, treated with salvage romidepsin therapy who relapsed after non-myeloablative allogeneic sibling peripheral blood stem cell transplant.
Discussion
Although histone deacetylase inhibitors have been investigated for many years, they have only recently been translated to clinical use as a therapy for malignancies. Furthermore, given their approval for a rare disease, clinicians often have limited experience with the dosing and side effects of histone deacetylase inhibitors.
Conclusion
This case report and literature review investigates the cardiac side effects of histone deacetylase inhibitors and illustrates the importance of cardiac monitoring prior to and during treatment. |
| doi_str_mv | 10.1177/1078155216673229 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1979815204</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_1078155216673229</sage_id><sourcerecordid>1979815204</sourcerecordid><originalsourceid>FETCH-LOGICAL-c431t-5e5d37b197e9530f7b58d0ef80d423808eba5595f00b1eaeaa8c9512dd56d8973</originalsourceid><addsrcrecordid>eNp1kMFLwzAYxYMobk7vniTguZqkzZJ4G2NOYSCIgreSNl-3jK2tSaruvzdzU0Tw9H3wfu89eAidU3JFqRDXlAhJOWd0OBQpY-oA9WkmREIUezmMf5STrd5DJ94vCSFSMHmMekwIIqlifVQ8NmtroPW2TrT3TWl1AINL7YzVJQ7Nhy1t2GBdGzwZT3G50PUc_A0eRcYDdtA2LnzJDt4svOOmwmEBeGUDOB06B6foqNIrD2f7O0DPt5On8V0ye5jej0ezpMxSGhIO3KSioEqA4impRMGlIVBJYjKWSiKh0JwrXhFSUNCgtSwVp8wYPjRSiXSALne5rWteO_AhXzadq2NlHkNVHIqRLFJkR5Wu8d5BlbfOrrXb5JTk21Hzv6NGy8U-uCvWYH4M3ytGINkBXs_hV-t_gZ89kH5A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1979815204</pqid></control><display><type>article</type><title>Romidepsin-associated cardiac toxicity and ECG changes: A case report and review of the literature</title><source>Sage Journals Online</source><creator>Rivers, Zachary T ; Oostra, Drew R ; Westholder, James S ; Vercellotti, Gregory M</creator><creatorcontrib>Rivers, Zachary T ; Oostra, Drew R ; Westholder, James S ; Vercellotti, Gregory M</creatorcontrib><description>Background
Romidepsin is a novel histone deacetylase inhibitor that is approved for the treatment of cutaneous and peripheral T-cell lymphoma in patients who have had at least one prior therapy. Romidepsin is generally well tolerated, though it comes with a risk of cardiac toxicities.
Objective
We report a case of electrocardiogram changes in a 64-year-old male with enteropathy-associated T-cell lymphoma, type 2, treated with salvage romidepsin therapy who relapsed after non-myeloablative allogeneic sibling peripheral blood stem cell transplant.
Discussion
Although histone deacetylase inhibitors have been investigated for many years, they have only recently been translated to clinical use as a therapy for malignancies. Furthermore, given their approval for a rare disease, clinicians often have limited experience with the dosing and side effects of histone deacetylase inhibitors.
Conclusion
This case report and literature review investigates the cardiac side effects of histone deacetylase inhibitors and illustrates the importance of cardiac monitoring prior to and during treatment.</description><identifier>ISSN: 1078-1552</identifier><identifier>EISSN: 1477-092X</identifier><identifier>DOI: 10.1177/1078155216673229</identifier><identifier>PMID: 27708192</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Case reports ; Chromatin ; EKG ; Heart ; Heart diseases ; Hematopoietic stem cells ; Histone deacetylase ; Inhibitors ; Literature reviews ; Lymphocytes T ; Lymphoma ; Peripheral blood ; Salvage ; Side effects ; T-cell lymphoma ; Toxicity</subject><ispartof>Journal of oncology pharmacy practice, 2018-01, Vol.24 (1), p.56-62</ispartof><rights>The Author(s) 2016</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c431t-5e5d37b197e9530f7b58d0ef80d423808eba5595f00b1eaeaa8c9512dd56d8973</citedby><cites>FETCH-LOGICAL-c431t-5e5d37b197e9530f7b58d0ef80d423808eba5595f00b1eaeaa8c9512dd56d8973</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925,79364</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27708192$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rivers, Zachary T</creatorcontrib><creatorcontrib>Oostra, Drew R</creatorcontrib><creatorcontrib>Westholder, James S</creatorcontrib><creatorcontrib>Vercellotti, Gregory M</creatorcontrib><title>Romidepsin-associated cardiac toxicity and ECG changes: A case report and review of the literature</title><title>Journal of oncology pharmacy practice</title><addtitle>J Oncol Pharm Pract</addtitle><description>Background
Romidepsin is a novel histone deacetylase inhibitor that is approved for the treatment of cutaneous and peripheral T-cell lymphoma in patients who have had at least one prior therapy. Romidepsin is generally well tolerated, though it comes with a risk of cardiac toxicities.
Objective
We report a case of electrocardiogram changes in a 64-year-old male with enteropathy-associated T-cell lymphoma, type 2, treated with salvage romidepsin therapy who relapsed after non-myeloablative allogeneic sibling peripheral blood stem cell transplant.
Discussion
Although histone deacetylase inhibitors have been investigated for many years, they have only recently been translated to clinical use as a therapy for malignancies. Furthermore, given their approval for a rare disease, clinicians often have limited experience with the dosing and side effects of histone deacetylase inhibitors.
Conclusion
This case report and literature review investigates the cardiac side effects of histone deacetylase inhibitors and illustrates the importance of cardiac monitoring prior to and during treatment.</description><subject>Case reports</subject><subject>Chromatin</subject><subject>EKG</subject><subject>Heart</subject><subject>Heart diseases</subject><subject>Hematopoietic stem cells</subject><subject>Histone deacetylase</subject><subject>Inhibitors</subject><subject>Literature reviews</subject><subject>Lymphocytes T</subject><subject>Lymphoma</subject><subject>Peripheral blood</subject><subject>Salvage</subject><subject>Side effects</subject><subject>T-cell lymphoma</subject><subject>Toxicity</subject><issn>1078-1552</issn><issn>1477-092X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp1kMFLwzAYxYMobk7vniTguZqkzZJ4G2NOYSCIgreSNl-3jK2tSaruvzdzU0Tw9H3wfu89eAidU3JFqRDXlAhJOWd0OBQpY-oA9WkmREIUezmMf5STrd5DJ94vCSFSMHmMekwIIqlifVQ8NmtroPW2TrT3TWl1AINL7YzVJQ7Nhy1t2GBdGzwZT3G50PUc_A0eRcYDdtA2LnzJDt4svOOmwmEBeGUDOB06B6foqNIrD2f7O0DPt5On8V0ye5jej0ezpMxSGhIO3KSioEqA4impRMGlIVBJYjKWSiKh0JwrXhFSUNCgtSwVp8wYPjRSiXSALne5rWteO_AhXzadq2NlHkNVHIqRLFJkR5Wu8d5BlbfOrrXb5JTk21Hzv6NGy8U-uCvWYH4M3ytGINkBXs_hV-t_gZ89kH5A</recordid><startdate>20180101</startdate><enddate>20180101</enddate><creator>Rivers, Zachary T</creator><creator>Oostra, Drew R</creator><creator>Westholder, James S</creator><creator>Vercellotti, Gregory M</creator><general>SAGE Publications</general><general>Sage Publications Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TO</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>20180101</creationdate><title>Romidepsin-associated cardiac toxicity and ECG changes: A case report and review of the literature</title><author>Rivers, Zachary T ; Oostra, Drew R ; Westholder, James S ; Vercellotti, Gregory M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c431t-5e5d37b197e9530f7b58d0ef80d423808eba5595f00b1eaeaa8c9512dd56d8973</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Case reports</topic><topic>Chromatin</topic><topic>EKG</topic><topic>Heart</topic><topic>Heart diseases</topic><topic>Hematopoietic stem cells</topic><topic>Histone deacetylase</topic><topic>Inhibitors</topic><topic>Literature reviews</topic><topic>Lymphocytes T</topic><topic>Lymphoma</topic><topic>Peripheral blood</topic><topic>Salvage</topic><topic>Side effects</topic><topic>T-cell lymphoma</topic><topic>Toxicity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rivers, Zachary T</creatorcontrib><creatorcontrib>Oostra, Drew R</creatorcontrib><creatorcontrib>Westholder, James S</creatorcontrib><creatorcontrib>Vercellotti, Gregory M</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>Journal of oncology pharmacy practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rivers, Zachary T</au><au>Oostra, Drew R</au><au>Westholder, James S</au><au>Vercellotti, Gregory M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Romidepsin-associated cardiac toxicity and ECG changes: A case report and review of the literature</atitle><jtitle>Journal of oncology pharmacy practice</jtitle><addtitle>J Oncol Pharm Pract</addtitle><date>2018-01-01</date><risdate>2018</risdate><volume>24</volume><issue>1</issue><spage>56</spage><epage>62</epage><pages>56-62</pages><issn>1078-1552</issn><eissn>1477-092X</eissn><abstract>Background
Romidepsin is a novel histone deacetylase inhibitor that is approved for the treatment of cutaneous and peripheral T-cell lymphoma in patients who have had at least one prior therapy. Romidepsin is generally well tolerated, though it comes with a risk of cardiac toxicities.
Objective
We report a case of electrocardiogram changes in a 64-year-old male with enteropathy-associated T-cell lymphoma, type 2, treated with salvage romidepsin therapy who relapsed after non-myeloablative allogeneic sibling peripheral blood stem cell transplant.
Discussion
Although histone deacetylase inhibitors have been investigated for many years, they have only recently been translated to clinical use as a therapy for malignancies. Furthermore, given their approval for a rare disease, clinicians often have limited experience with the dosing and side effects of histone deacetylase inhibitors.
Conclusion
This case report and literature review investigates the cardiac side effects of histone deacetylase inhibitors and illustrates the importance of cardiac monitoring prior to and during treatment.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>27708192</pmid><doi>10.1177/1078155216673229</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1078-1552 |
| ispartof | Journal of oncology pharmacy practice, 2018-01, Vol.24 (1), p.56-62 |
| issn | 1078-1552 1477-092X |
| language | eng |
| recordid | cdi_proquest_journals_1979815204 |
| source | Sage Journals Online |
| subjects | Case reports Chromatin EKG Heart Heart diseases Hematopoietic stem cells Histone deacetylase Inhibitors Literature reviews Lymphocytes T Lymphoma Peripheral blood Salvage Side effects T-cell lymphoma Toxicity |
| title | Romidepsin-associated cardiac toxicity and ECG changes: A case report and review of the literature |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T22%3A10%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Romidepsin-associated%20cardiac%20toxicity%20and%20ECG%20changes:%20A%20case%20report%20and%20review%20of%20the%20literature&rft.jtitle=Journal%20of%20oncology%20pharmacy%20practice&rft.au=Rivers,%20Zachary%20T&rft.date=2018-01-01&rft.volume=24&rft.issue=1&rft.spage=56&rft.epage=62&rft.pages=56-62&rft.issn=1078-1552&rft.eissn=1477-092X&rft_id=info:doi/10.1177/1078155216673229&rft_dat=%3Cproquest_cross%3E1979815204%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c431t-5e5d37b197e9530f7b58d0ef80d423808eba5595f00b1eaeaa8c9512dd56d8973%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1979815204&rft_id=info:pmid/27708192&rft_sage_id=10.1177_1078155216673229&rfr_iscdi=true |